Form 4: BioLargo Director Acquires Options as Compensation for Board Service
SEC Form 4 Filing
BioLargo director Jack B. Strommen received options to purchase 78,947 shares of common stock as compensation for his board service.
Summary
- Jack B. Strommen, a director at BioLargo, Inc., was granted an option to purchase 78,947 shares of common stock.
- The options were granted as payment for $15,000 in fees for his board service during the most recent quarter.
- The options were issued under the company's 2024 Equity Incentive Plan.
- The exercise price of the options is $0.19 per share.
- The options vest immediately and expire on December 31, 2034.
- Following this transaction, Mr. Strommen directly owns 2,061,395 shares of BioLargo common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of stock options as compensation, which is generally viewed positively as it aligns director interests with shareholders. There are no indications of negative sentiment.
Positives
- The issuance of options aligns director compensation with company performance.
- The use of equity-based compensation can help conserve cash for the company.
Risks
- The exercise of these options could potentially dilute existing shareholders' equity.
- The value of the options is dependent on the future performance of BioLargo's stock price.
Industry Context
The use of stock options as compensation for board members is a common practice in publicly traded companies, aligning the interests of directors with those of shareholders.
Comparison to Industry Standards
- Granting stock options to directors is a standard practice across many industries, particularly in growth-oriented companies.
- The specific number of options and their value are typically determined by the company's compensation policy and the director's level of involvement.
- Companies like Xometry and Beyond Meat also use stock options as part of their compensation packages for directors.
Stakeholder Impact
- Shareholders may experience minor dilution if the options are exercised.
- The compensation structure aligns the director's interests with the long-term success of the company.
Key Dates
| Date | Description |
|---|---|
| 07/03/2017 | Date of the Limited Power of Attorney for Section 16 Reporting Obligations. |
| 12/31/2024 | Date of the option grant and the date the options become exercisable. |
| 12/31/2034 | Expiration date of the options. |
| 01/03/2025 | Date the Form 4 was signed. |
Keywords
BioLargo, Director, Options, Equity Compensation, Board Service, Stock Options, Form 4, BLGO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.